Jump to content

Paroxetine: Difference between revisions

From Pharmacopedia
[checked revision][unchecked revision]
Pharmacopedia: remove contraindications parameter
Pharmacopedia: add <pharmaInteractions/>
Line 22: Line 22:
| dosing            =  
| dosing            =  
| effects            =  
| effects            =  
| interactions      =  
| interactions      = <pharmaInteractions/>
| pregnancy_details  =  
| pregnancy_details  =  
| monitoring        =  
| monitoring        =  

Revision as of 03:31, 14 May 2026

SSRI, Antidepressant
Paroxetine
Paxil

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions9 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 normal metabolizer monitor CPIC A 70 / 100
CPIC rec 8094697 [Strong]: Initiate therapy with recommended starting dose CPIC pair-level A (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 25974703, 37032427]
Phenotype:CYP2D6 ultrarapid metabolizer prefer alternative CPIC A 55 / 100
CPIC rec 8094686 [Moderate]: Select alternative drug not predominantly metabolized by CYP2D6. CPIC pair-level A (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 25974703, 37032427] FDA labeling (Drug Interactions, Clinical Pharmacology)
Phenotype:CYP2D6 poor metabolizer dose reduce 50 CPIC A 55 / 100
CPIC rec 8094706 [Moderate]: Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose as compared to normal metabolizers. CPIC pair-level A (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 25974703, 37032427] FDA labeling (Drug Interactions, Clinical Pharmacology)
Phenotype:CYP2D6 intermediate metabolizer dose reduce 25 CPIC A 25 / 100
CPIC rec 8094702 [Optional]: Consider a lower starting dose and slower titration schedule as compared to normal metabolizers. CPIC pair-level A (CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants) [PMID 25974703, 37032427] FDA labeling (Drug Interactions, Clinical Pharmacology)
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP2D6 inhibitor strong Primary 90 / 100
FDA Drug Interactions Table: strong index inhibitor of CYP2D6.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Codeine pk lowers via CYP2D6 Inferred 90 / 100
Paroxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Codeine is a prodrug_activated_by of CYP2D6 (intensity 100). Derived: Codeine exposure lowered.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure lowered)
Desipramine pk raises via CYP2D6 Inferred 72 / 100
Paroxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Desipramine is a substrate_major of CYP2D6 (intensity 80). Derived: Desipramine exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Dextromethorphan pk raises via CYP2D6 Inferred 72 / 100
Paroxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Nebivolol pk raises via CYP2D6 Inferred 72 / 100
Paroxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Nebivolol is a substrate_major of CYP2D6 (intensity 80). Derived: Nebivolol exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)

Patient experience

Fluoxetine via Category:Antidepressants👤 exp n/a/5 outcome n/a (n=1)⚕️ exp 1.0/5 outcome +33.0 (n=1)

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Pharmacy
Common uses
Classification(s)
Classes
SSRI, Antidepressant
Pharmacology
Purported mechanism
Selective serotonin reuptake inhibitor
Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the full disclaimer.